Bure Equity AB (publ)

Bure Equity AB (publ), a private equity and venture capital firm established on November 23, 1992, and headquartered in Stockholm, Sweden, pursues a wide range of investment strategies. The firm adopts a flexible approach, targeting both publicly traded and privately held small and medium-sized enterprises (SMEs) within knowledge-intensive service industries. Its investment scope is comprehensive, covering various stages from early-stage and growth capital to mature buyouts, recapitalizations, special situations, and even specific funding methods like secondary direct, PIPES, and bridge financing. Bure Equity primarily focuses its investments, typically ranging from $5 million to $100 million, within developed Nordic and European markets. It diversifies its portfolio across numerous sectors, including education, communication, medical technology, consumer goods, financial services, industrial production, healthcare, information technology, and professional services. The firm aims to be a leading shareholder, acquiring majority stakes and exerting significant control over its investee companies. While not having a rigid divestment plan, it generally holds investments for a timeframe of three to five years, utilizing its own balance sheet for funding.

Bure Equity AB (publ) trades as BURE.ST on STO. The company is classified in Financial Services / Asset Management and reports in SEK.

The current profile places the business in Asset Management. This section is intended to summarize the operating segments, products, geographies, and main revenue lines from official filings.

Detailed operating-segment data is not available for this symbol yet.

Use this area for management strategy, capital allocation priorities, target markets, and measurable goals from the latest annual report or investor presentation.

The app now provides the structure, but exact strategic claims should come from official company documents before being treated as a finished investment thesis.

Bure Equity AB (publ) can be compared against peers such as Arion banki hf., Creades AB, Kinnevik AB, Linc AB, MedCap AB (publ), Ratos AB (publ).

A complete thesis should compare growth, margins, balance-sheet risk, valuation multiples, and market position against direct competitors.

Current signals to investigate include market capitalization of $19.80B, beta of 1.29, and return on equity of N/A.

This section should be validated with evidence such as durable margins, brand strength, regulation, switching costs, cost advantage, distribution, or technology.

Key risks should include financial leverage, cyclicality, customer concentration, regulatory exposure, currency risk, and execution risk.

BURE.ST currently shows total debt of N/A and beta of 1.29. Missing data should be treated as a research gap, not as low risk.

Production-capacity detail is not available as structured data yet. For industrial, defense, semiconductor, or real-estate companies, this should be reviewed from annual reports and investor presentations.

No structured backlog field is available yet. If the company reports backlog, review the relevant filing section before adding it to the thesis.

Use this section for major contracts, product launches, construction projects, acquisitions, or strategic programs that can materially affect valuation.

No recent SEC-style filings are available for this symbol yet.

Customer concentration is not available as structured data here. Add it from official filings when a company discloses material customers or revenue concentration.

Supplier concentration and critical supply-chain dependencies are not available as structured data here. This should be researched from annual reports and risk disclosures.

Company website: https://www.bure.se/en/home-en

For US-listed stocks, verify the thesis against official filings, earnings call transcripts, and company investor relations materials.